Renatus Inc., a pharmaceutical company focused on developing cholesterol metabolism modulators, was selected for the Merck’s 2024 Advance Biotech Grant Program – Korea. The Merck’s Advance Biotech Grant Program has recognized innovative biotechnology companies worldwide since 2014. The award ceremony was held at BIOPLUS-INTERPHEX KOREA 2024 on July 11.

To keep updated, please follow:

LinkedIn Page: https://www.linkedin.com/company/renatustx/ 

About RENATUS

Renatus is a pharma company thriving to develop next generation cyclodextrins to provide safe treatment options for patients living with cholesterol-associated diseases. Renatus seeks to provide critical impact in developing translational cyclodextrin therapies and fulfill its vision to protect the world from various cholesterol-associate diseases. For more information, please visit www.renatustx.com